Zobrazeno 1 - 10
of 49
pro vyhledávání: '"M. E. Martinuzzo"'
Autor:
M. S. Lopez, A. Adrover, Ezequiel D. Kataife, M. E. Martinuzzo, Federico G. Mileo, G. García Fornari
Publikováno v:
Critical Care
Background Severe traumatic injury continues to present challenges to healthcare systems around the world, and post-traumatic bleeding remains a leading cause of potentially preventable death among injured patients. Now in its fifth edition, this doc
Autor:
Luis H Barrera, Estela S Viñuales, Ricardo Forastiero, M. E. Martinuzzo, Marina Sol López, José Oyhamburu, Jose Ceresetto, Cristina Duboscq
Publikováno v:
Clinical Laboratory. 64
BACKGROUND Rivaroxaban oral anticoagulant does not need laboratory monitoring, but in some situations plasma level measurement is useful. The objective of this paper was to verify analytical performance and compare two rivaroxaban calibrated anti Xa
Autor:
M. E. Martinuzzo, Graciela S Cerrato, Ricardo Forastiero, Yolanda Adamczuk, Maria Luisa Iglesias Varela
Publikováno v:
International Journal of Laboratory Hematology. 34:208-213
Summary Introduction: The updated guidelines for lupus anticoagulant (LA) diagnosis indicate locally calculate the cut-off values of the index of circulating anticoagulant (ICA) and the clotting time in seconds (s) for mixing studies and % of correct
Autor:
Ricardo Forastiero, M. E. Martinuzzo
Publikováno v:
Lupus. 17:872-877
Antiphospholipid syndrome (APS) is a clinical autoimmune disorder characterised by thrombosis, venous or arterial, and recurrent pregnancy morbidity in association with the persistence of antiphospholipid antibodies (aPL). The clinical variety of aPL
Autor:
L. Puga, Maria Luisa Iglesias Varela, Edgardo Bottaro, M. E. Martinuzzo, Gabriela de Larrañaga, Silvia Perés Wingeyer, Marcelo Corti, Jorge A. Benetucci, Ricardo Forastiero, Raúl H. Figueroa, Yolanda Adamczuk
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 15:340-347
Several reports have described an increased incidence of osteonecrosis in human immunodeficiency virus—infected patients (HIV+), but the cause has not been established. The association between thrombophilia and osteonecrosis in HIV+ was studied. A
Autor:
L. Chavez, Andrés Ruf, Fernando Gruz, Graciela S Cerrato, Ricardo Forastiero, Federico G. Villamil, S. Perez Lloret, M. E. Martinuzzo, Claudia Fuxman, G. Podestá, V. Descalzi, F. Cairo
Publikováno v:
Journal of Thrombosis and Haemostasis. 5:P-T
Autor:
M. E. Martinuzzo, Ricardo Forastiero
Publikováno v:
Expert review of clinical immunology. 11(11)
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by clinical symptoms of vascular thrombosis and/or pregnancy morbidity in the presence of autoimmune antiphospholipid antibodies (aPL). Current laboratory APS criteria include th
Publikováno v:
Lupus. 14:129-136
The antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) in patients with thromboembolic complications. In APS, most aPL are autoantibodies to β2-glycoprotein I and prothrombin, which play a major rol
Publikováno v:
Journal of Thrombosis and Haemostasis. 1:1764-1770
The hemostatic process is tightly regulated by several antithrombotic mechanisms. Among them, protein Z (PZ)-dependent protease inhibitor (ZPI) potently inhibits factor (F)Xa in a manner dependent on calcium ions, phospholipids and PZ. Autoimmune ant
Publikováno v:
Journal of Thrombosis and Haemostasis. 1:718-724
As the activity of the tissue factor pathway inhibitor (TFPI) may be impaired in patients with antiphospholipid antibodies (aPL), 162 aPL patients were evaluated for autoantibodies to recombinant TFPI (anti-TFPI) using an optimized ELISA. Anti-TFPI (